Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 80, Issue 2, 1998, Pages 221-225

  Friedrich, Michael ^a   Mink, Dieter ^a   Villena Heinsen, Carlos ^a   Woll Hermann, Astrid ^a   Schmidt, Werner ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Breast cancer; Endocervical cell hyperplasia; Maturation index; Metaplasia; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL HYPERPLASIA; CELL PROLIFERATION; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATURATION; METAPLASIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; UTERINE CERVIX EPITHELIUM; VAGINA EPITHELIUM;

EID: 0032189241     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00117-1     Document Type: Article

References (25)

1. [1] Koss LG. Diagnostic cytology and its histopathologic bases. 3rd ed. Philadelphia: JB Lippincott, 1979.
2. [2] Berg JW, Dunfee GR. Cytological presentation of endometrial carcinoma. Cancer 1958;11:158-72.
3. [3] Wied GL, Bibbo M, Keebler C. Evaluation of endocrinologic condition by exfoliative cytology. In: Wied GL, Keebler CM, Koss LC, Reagan JW, editors. Compendium of diagnostic cytology. 6th ed. Chicago: Tutorial of Cytology, 1988:33-42.
4. [4] Koss LG. Cytologic evaluation of the endocrine status of the woman. In: Koss LG, editor. Diagnostic cytology and its histopathologic bases. 3rd ed. Philadelphia: JB Lippincott, 1979:203-22.
5. [5] Helmerhorst TJM, Dijkhuizen GH, Veldhuizen RW, Stolk JG. Microglandular hyperplasia - a complicating factor in the diagnosis of cervical intraepithelial neoplasia. Eur J Obstet Gynec Reprod Biol 1987;17:53-9.
6. [6] Fornander T, Rutquist LE, Cedermark B, Glas U, Mattson A. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;1:117-20.
7. [7] Fischer B, Costantino J, Redmond CK, Fisher ER, Wickerham L, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP), B-14 [Prior annotation incorrect] [see comment citations in Medline]. J Natl Cancer Inst 1994;86:527-37.
8. [8] Hardell L. Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 1988;3:563.
9. [9] Killacke MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
10. [10] Soost HJ, Bauer S. Gynäkologische Zytodiagnostik. [Gynecologic cytologic diagnostic]. 5th ed. Stuttgart: Thieme, 1990.
11. [11] Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as single agent. J Natl Cancer Inst 1991;83:1488-91.
12. [12] Boccardo F, Bruzzi P, Rubagotti A, Nicolo G, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981;30:281-5.
13. [13] Ferrazzi E, Cartel G, Mattarazzo R, Fiorentino M. Estrogen-like action of tamoxifen on vaginal epithelium. Br Med J 1977;1:1351-2.
14. [14] Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumours in the athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183-7.
15. [15] Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effect of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006-10.
16. [16] Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-5.
17. [17] Anzai Y, Holinka CF, Kuramato H, Gurdipe E. Stimulatory effect of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 1989;49:2362-5.
18. [18] Gallo MA, Kaufmann D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 1997;24(1):1-80.
19. [19] Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 1992;45:118-28.
20. [20] Rutquist LE, Johansson H, Signomklao T, Johannson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-50.
21. [21] Fisher B. Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 1996;14(3):1027-39.
22. [22] Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995;87:1359-64.
23. [23] Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-33.
24. [24] Adami HO, Krusemo UB, Bergkvist L, Persson I, Pettersson P. On the age-dependant association between cancer of the breast and of the endometrium. A nationwide cohort study. Br J Cancer 1987;55:77-80.
25. [25] Rayter Z, Gazet JC, Shepherd J, et al. Gynecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol 1994;20:134-40.